

LIFE HEALTHCARE GROUP HOLDINGS LIMITED

(Incorporated in the Republic of South Africa)

(Registration number: 2003/002733/06)

ISIN: ZAE000145892

Share Code: LHC

("the Company")

LIFE HEALTHCARE FUNDING LIMITED

(Incorporated in the Republic of South Africa with limited liability under registration number

2016/273566/06)

Bond company code: LHF1

("Life Healthcare Funding")

CHANGES TO THE BOARD OF DIRECTORS AND CHANGES TO THE TERMS OF REFERENCE FOR THE NOMINATIONS AND GOVERNANCE COMMITTEE

Board appointments

In keeping with the Board's succession plan and strategy, the Company is pleased to announce the appointments of Mr Lars Holmqvist and Dr Jeanne Bolger as independent non-executive directors of the Board, with effect from 1 August 2022.

Lars has over 25 years' experience in the sectors of health, pharmaceuticals, biotechnology and medical diagnostics and is a former senior corporate executive in the global life sciences sector. He has an accomplished portfolio as a non-executive director, with significant experience in management, finance and sales and marketing, across international companies and sectors. Lars currently chairs the Board of Biovica International AB, a Swedish based cancer diagnostics company and he also serves as a non-executive director of Vitrolife AB, H.Lundbeck AS and ALK Abello AS.

Lars' previous executive roles included serving as President of Life Science & Diagnostic Group at Agilent Technologies Inc, President & CEO of Dako AS and President International for Applied Biosystems Inc. He also served as a Senior Advisor to Bain Capital Private Equity and was a director at Tecan Group AG. Lars currently resides in Sweden.

Jeanne is a pharmaceutical physician with 35 years' experience in leadership roles, spanning commercial strategy, medical and regulatory affairs, business development and venture investments. Jeanne joined Johnson and Johnson (J&J) Innovation – JJDC, the Corporate Venture Fund of J&J in 2013. Prior to this, Jeanne had been Global Head of Scientific Licensing in the Pharmaceuticals Business Development Group at Janssen, J&J. Over the past nine years, Jeanne has advised on Seed, Series A, Series B and syndicated biotechnology and diagnostics investments across therapy areas. She was a member of the Investment Committee for investments in robotics, Big Data and Digital Health technologies. Jeanne has served as a non-executive director on multiple J&J Investee company boards and their Audit and Remuneration sub-committees.

Jeanne recently retired from her role as Vice President, Venture Investments at JJDC. She is currently an independent non-executive Chair of a European Venture Capital-backed biotech company and is a venture partner at a European Venture Capital Fund. She has also been appointed to the Board of a new Translational Fund at the Sir Francis Crick Institute in London, UK. Jeanne currently resides in Ireland.

Dr Victor Litlhakanyane, Chairman of the Board stated, “The Board is delighted to welcome two accomplished international directors to our Board, as we continue to focus on our offshore footprint. We have no doubt that their significant global experience in the healthcare sector will add tremendous insight and value to the Company.”

Board committee changes

With effect from the date of their appointments, Lars will serve on the Investment and Audit Committees to complement the skillset of these Committees and Jeanne will serve on the Investment and Clinical Committees of the Company.

Ms Audrey Mothupi, a current independent non-executive director on the Board, will step down from the Audit Committee with effect from 1 August 2022, to focus her commitments on the other Board Committees that she serves on. The Board would like to thank Audrey for her invaluable contribution to the Audit Committee during her tenure.

Advocate Mahlape Sello has been appointed as a member on the Social, Ethics and Transformation Committee, with effect from 1 August 2022.

Changes to the Terms of Reference for the Nominations and Governance Committee

Shareholders and noteholders are advised that the Nominations and Governance Committee’s terms of reference have been updated and the updated Terms of Reference will be available at <https://www.lifehealthcare.co.za/investor-relations/domestic-medium-term-note-programme/>.

Enquiries:

Joshila Ranchhod – Group Company Secretary

E-mail: joshilar@life.co.za

28 July 2022

Dunkeld

Sponsor and Debt Sponsor

RAND MERCHANT BANK (a division of FirstRand Bank Limited)
